Actinium (225ac) Lintuzumab Satetraxetan

Actinium (225ac) Lintuzumab Satetraxetan Uses, Dosage, Side Effects, Food Interaction and all others data.

Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).

Trade Name Actinium (225ac) Lintuzumab Satetraxetan
Generic Lintuzumab satetraxetan AC-225
Lintuzumab satetraxetan AC-225 Other Names 225Ac-HuM195, 225Ac-lintuzumab, Actinium (225ac) lintuzumab satetraxetan, Actinium AC 225 lintuzumab, Actinium AC-225 lintuzumab, Actinium-225-labeled humanized anti-cd33 monoclonal antibody HUM195, HUM-195 AC-225, Lintuzumab actinium Ac-225, Lintuzumab satetraxetan AC-225
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Actinium (225ac) Lintuzumab Satetraxetan
Actinium (225ac) Lintuzumab Satetraxetan

Innovators Monograph

You find simplified version here Actinium (225ac) Lintuzumab Satetraxetan


*** Taking medicines without doctor's advice can cause long-term problems.
Share